Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
24 hedge funds and large institutions have $15.8M invested in Biolase, Inc. in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 7 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $17.8M → $15.8M (-$2.01M)
14% less funds holding
Funds holding: 28 → 24 (-4)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$7.05M |
| 2 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
+$113K |
| 3 |
TA
Teton Advisors
Rye,
New York
|
+$70.3K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
+$21.1K |
| 5 |
GI
GAMCO Investors
Greenwich,
Connecticut
|
+$21.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$3.21M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$32K |
| 3 |
Millennium Management
New York
|
-$29K |
| 4 |
VF
Virtu Financial
New York
|
-$21.1K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$20K |
BIOL Hedge Fund Activity: Q4 2017 in Review
24 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q4 2017, worth a combined $15.8M — down 11% from $17.8M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BIOL and 4 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 11 added.
The largest buyer was Oracle Investment Management, adding an estimated $7.05M. The largest seller was Camber Capital Management, exiting entirely with an estimated $3.21M sold.
- 24 institutional investors held Biolase, Inc. (BIOL) as of Q4 2017, down from 28 in Q3 2017.
- Funds reported $15.8M of Biolase, Inc. stock for Q4 2017, down 11% quarter-over-quarter.
- 4 funds opened new Biolase, Inc. positions in Q4 2017 and 7 closed out, a net change of -3 holders.
- The largest Biolase, Inc. buyer in Q4 2017 was Oracle Investment Management, an estimated $7.05M added.
- The largest Biolase, Inc. seller in Q4 2017 was Camber Capital Management, an estimated $3.21M sold.
Based on aggregated 13F filings for Q4 2017.